Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004476307 | SCV004971595 | uncertain significance | Inborn genetic diseases | 2023-12-09 | criteria provided, single submitter | clinical testing | The c.2366A>G (p.H789R) alteration is located in exon 11 (coding exon 11) of the TRIP11 gene. This alteration results from a A to G substitution at nucleotide position 2366, causing the histidine (H) at amino acid position 789 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV005104758 | SCV005759920 | uncertain significance | Achondrogenesis, type IA | 2024-09-16 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 789 of the TRIP11 protein (p.His789Arg). This variant is present in population databases (rs139118524, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with TRIP11-related conditions. Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt TRIP11 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |